{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:18:34Z","timestamp":1778692714491,"version":"3.51.4"},"reference-count":50,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Vascular abnormalities (VAs) are a broad category of disorders that include vascular malformations (inadequate embryologic blood vessel development) and vascular tumors (characterized by vascular cell hyperplasia). This sometimes-complicated pathology is increasingly being treated with mTOR inhibitors, particularly sirolimus (rapamycin). Only a limited number of neonates treated with sirolimus have been reported in the literature to date, and there is no consensus regarding the optimal treatment regimen for vascular anomalies in this population. The objective of our narrative review is to summarize the most recent information from the specialized literature regarding the efficacy and safety of sirolimus in newborns. Methods: A methodological search was performed through the available data concerning the indications and safety when using sirolimus to treat VAs in newborns. We evaluated articles from the Embase and PubMed academic search engines using the following search terms: (vascular anomalies OR vascular tumors OR venous malformations OR lymphatic malformations OR capillary malformations) AND (neonate) AND (sirolimus OR rapamycin). Results: We identified a lack of consensus regarding indications for treatment initiation, optimal dosing regimens, and duration of therapy. In most published studies, neonates were analyzed within broader pediatric cohorts that included patients up to 18 years of age, rather than as a distinct population. Moreover, only a limited number of investigations have specifically focused on neonates treated with sirolimus and evaluated outcomes from a neonatal subgroup perspective. The available evidence largely consists of isolated case series and reports describing sirolimus use in fetuses and neonates, most commonly for lymphatic malformations or kaposiform hemangioendothelioma; in some instances, sirolimus was administered in combination with propranolol, corticosteroids, or other therapeutic modalities. Nevertheless, across studies and case reports involving fetuses or neonates, sirolimus is generally reported to be effective and well tolerated, with adverse effects that are minimal and reversible. Conclusions: For neonates and even fetuses with large, complex VAs, sirolimus appears to be an effective treatment with no serious adverse events reported to date. Decisions regarding off-label sirolimus initiation should be made by a multidisciplinary team, and parents must be thoroughly informed about potential adverse events. Well-designed randomized controlled trials or high-quality observational studies are needed to further evaluate the efficacy and safety of sirolimus in the neonatal population.<\/jats:p>","DOI":"10.3390\/jcm15103739","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:26:37Z","timestamp":1778689597000},"page":"3739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sirolimus Treatment for Complex Fetal and Neonatal Vascular Anomalies: Emerging Evidence and Safety Considerations"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-8011","authenticated-orcid":false,"given":"Elena","family":"\u021aarc\u0103","sequence":"first","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7859-840X","authenticated-orcid":false,"given":"Elena","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-4244","authenticated-orcid":false,"given":"L\u0103cr\u0103mioara Ionela","family":"Butnariu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solange Tamara","family":"Ro\u0219u","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina Costina","family":"Luca","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidonia","family":"Susanu","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Saint Mary Emergency Children Hospital, 700309 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-8795","authenticated-orcid":false,"given":"Vasile Valeriu","family":"Lupu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6305-626X","authenticated-orcid":false,"given":"Eduard Vasile","family":"Ro\u0219u","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Popovici","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viorel","family":"\u021aarc\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Apollonia University, Strada P\u0103curari nr. 11, 700511 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.det.2022.06.007","article-title":"Vascular Anomalies: Nomenclature and Diagnosis","volume":"40","author":"Andrews","year":"2022","journal-title":"Dermatol. Clin."},{"key":"ref_2","unstructured":"(2025, December 28). International Society for the Study of Vascular Anomalies. Available online: https:\/\/www.issva.org\/classification."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jamadermatol.2021.3459","article-title":"Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial","volume":"157","author":"Maruani","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/gim.2016.220","article-title":"Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing","volume":"19","author":"Kuentz","year":"2017","journal-title":"Genet. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/JID.2015.331","article-title":"Molecular genetics of the PI3K-AKT-mTOR pathway in genodermatoses: Diagnostic implications and treatment opportunities","volume":"136","author":"Vahidnezhad","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/exd.12826","article-title":"Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Vahidnezhad","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1093\/hmg\/ddt198","article-title":"Venous malformation\u2013causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB","volume":"22","author":"Uebelhoer","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2340\/00015555-2300","article-title":"Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: A systematic review","volume":"96","author":"Nadal","year":"2016","journal-title":"Acta Derm.-Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102284","DOI":"10.1016\/j.jvsv.2025.102284","article-title":"Effectiveness and safety of sirolimus in the treatment of venous malformations: A meta-analysis of prospective studies","volume":"13","author":"Wang","year":"2025","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MOH.0000000000000498","article-title":"Rapamycin and treatment of venous malformations","volume":"26","author":"Seront","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41372-024-01868-9","article-title":"Sirolimus for vascular anomalies in the first year of life: A systematic review","volume":"44","author":"Cavazos","year":"2024","journal-title":"J. Perinatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Karastaneva, A., Gasparella, P., Tschauner, S., Crazzolara, R., Kropshofer, G., Modl, M., Pfleger, A., Burmas, A., Pocivalnik, M., and Ulreich, R. (2022). Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies-Insights from a Retrospective Case Series. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.857436"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Scuglia, M., Conforti, A., Valfr\u00e8, L., Totonelli, G., Iacusso, C., Iacobelli, B.D., Meucci, D., Viggiano, M., Fusaro, F., and Diociaiuti, A. (2021). Operative Management of Neonatal Lymphatic Malformations: Lesson Learned From 57 Consecutive Cases. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.709223"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s00405-022-07378-8","article-title":"Efficacy of sirolimus in children with lymphatic malformations of the head and neck","volume":"279","author":"Wiegand","year":"2022","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e246265","DOI":"10.1136\/bcr-2021-246265","article-title":"Sirolimus used for treatment of retroperitoneal arteriovenous malformation in a premature neonate","volume":"15","author":"Chetan","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_17","unstructured":"(2026, February 02). Prospective Evaluation of the Efficacy of Sirolimus (Rapamune\u00ae) in the Treatment of Severe Arteriovenous Malformations (MAV-RAPA), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02042326."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13023-022-02608-y","article-title":"French national diagnosis and care protocol (PNDS, protocole national de diagnostic et de soins): Cystic lymphatic malformations","volume":"18","author":"Leboulanger","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Honnorat, M., Viremouneix, L., Ayari, S., Guibaud, L., Coste, K., Claris, O., and Butin, M. (2020). Early Adjuvant Medication with the mTOR Inhibitor Sirolimus in a Preterm Neonate with Compressive Cystic Lymphatic Malformation. Front. Pediatr., 8.","DOI":"10.3389\/fped.2020.00418"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1684\/ejd.2018.3441","article-title":"Efficacy of sirolimus combined with sclerotherapy for giant cervical lymphatic macrocystic malformations: Two newborn cases","volume":"29","author":"Meurisse","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1089\/lrb.2018.0068","article-title":"Oral sirolimus: An option in the management of neonates with life-threatening upper airway lymphatic malformations","volume":"17","author":"Triana","year":"2019","journal-title":"Lymphat. Res. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"162223","DOI":"10.1016\/j.jpedsurg.2025.162223","article-title":"Management, Trends, and Recommendations for Intra-abdominal Lymphatic Malformations: A Single-Center Retrospective Review","volume":"60","author":"Vore","year":"2025","journal-title":"J. Pediatr. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/pd.5925","article-title":"Fetal therapy using rapamycin for a rapidly enlarging, obstructive, cervical lymphatic malformation: A case report","volume":"41","author":"Livingston","year":"2021","journal-title":"Prenat. Diagn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e28036","DOI":"10.1002\/pbc.28036","article-title":"Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus","volume":"67","author":"Iacobas","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jss.2024.08.026","article-title":"Ex Utero Intrapartum Treatment for Prenatally Diagnosed Cervicofacial Lymphatic Malformations","volume":"303","author":"Gillipelli","year":"2024","journal-title":"J. Surg. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/lary.26780","article-title":"Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation","volume":"128","author":"Strychowsky","year":"2018","journal-title":"Laryngoscope"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103126","DOI":"10.1016\/j.epsc.2025.103126","article-title":"Large congenital lymphatic venous malformation in a twin pregnancy: A case report","volume":"123","author":"Avila","year":"2025","journal-title":"J. Pediatr. Surg. Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.12998\/wjcc.v9.i23.6929","article-title":"Sirolimus treatment for neonate with blue rubber bleb nevus syndrome: A case report","volume":"9","author":"Yang","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pi, M., Zhao, L., Xu, W., Xu, M., and Ding, Y. (2023). Case report: Blue rubber bleb nevus syndrome with Kasabach-Merritt phenomenon in a neonate. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1131094"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40272-025-00708-3","article-title":"Effective Sirolimus Use in Prenatal and Postnatal Management of Symptomatic Extensive Congenital Capillary-Lymphatic-Venous Malformations (CLVMs): A Report of Two Cases","volume":"27","author":"Klosowska","year":"2025","journal-title":"Paediatr. Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s44161-023-00280-4","article-title":"A case report of sirolimus use in early fetal management of lymphatic malformation","volume":"2","author":"Seront","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/kjm2.12537","article-title":"Sirolimus for neonatal Klippel-Trenaunay syndrome with chylothorax","volume":"38","author":"Kuo","year":"2022","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_33","first-page":"1375","article-title":"Differential diagnosis difficulties related to infantile hemangioma\u2014Case report and literature review","volume":"60","author":"Cojocaru","year":"2019","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1186\/s13023-025-04115-2","article-title":"PI3K\/AKT\/mTOR axis in vascular malformations: From molecular insights to targeted clinical trials","volume":"20","author":"Zheng","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e37706","DOI":"10.1097\/MD.0000000000037706","article-title":"Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report","volume":"103","author":"Cheng","year":"2024","journal-title":"Medicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"161932","DOI":"10.1016\/j.jpedsurg.2024.161932","article-title":"Analysis of Risk Factors for Kasabach Merritt Phenomenon in Children with Kaposiform Hemangioendothelioma","volume":"60","author":"Chen","year":"2025","journal-title":"J. Pediatr. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1179545X17699849","DOI":"10.1177\/1179545X17699849","article-title":"Kasabach-Merritt Phenomenon: Classic Presentation and Management Options","volume":"10","author":"Mahajan","year":"2017","journal-title":"Clin. Med. Insights Blood Disord."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109497","DOI":"10.1016\/j.ijscr.2024.109497","article-title":"Sirolimus monotherapy for Kasabach-Merritt phenomenon in a neonate; Case report","volume":"117","author":"Nakamura","year":"2024","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2021014027","article-title":"Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: A randomized clinical trial","volume":"139","author":"Ji","year":"2022","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Shin, S., and Shim, Y.J. (2025). Neonatal Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon Presenting as Severe Airway Obstruction at Birth: A Case Report. Children, 12.","DOI":"10.3390\/children12111429"},{"key":"ref_41","first-page":"e155","article-title":"Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon in a Neonate: A Case Report","volume":"13","author":"Zheng","year":"2025","journal-title":"Eur. J. Pediatr. Surg. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3892\/etm.2021.10531","article-title":"Antiproliferative therapy with sirolimus and propranolol for congenital vascular anomalies in newborns (Case reports)","volume":"22","author":"Bizubac","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jamadermatol.2020.5180","article-title":"Mucocutaneous Adverse Events Associated with Oral Sirolimus for the Treatment of Vascular Anomalies","volume":"157","author":"Grenier","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1542\/peds.2017-1044","article-title":"Pneumocystis jirovecii pneumonia during Sirolimus therapy for kaposiform Hemangioendothelioma","volume":"141","author":"Russell","year":"2018","journal-title":"Pediatrics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijporl.2017.11.034","article-title":"Sirolimus for management of complex vascular anomalies\u2014A proposed dosing regimen for very young infants","volume":"105","author":"Czechowicz","year":"2018","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/bcp.15202","article-title":"Effective low\u2013dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach\u2013Merritt phenomenon in young infants","volume":"88","author":"Harbers","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-018-0934-z","article-title":"Sirolimus is efficacious in treatment for extensive and\/or complex slow-flow vascular malformations: A monocentric prospective phase II study","volume":"13","author":"Hammer","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/pd.6834","article-title":"In-Utero Therapy for Fetal Vascular Anomalies: Efficacy and Tolerance of Sirolimus Administered to the Pregnant Patient","volume":"45","author":"Iacobas","year":"2025","journal-title":"Prenat. Diagn."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jvsv.2019.09.007","article-title":"Sclerotherapy for lymphatic malformations of head and neck: Systematic review and meta-analysis","volume":"8","author":"Balakrishnan","year":"2020","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Butnariu, L.I., Gorduza, E.V., Florea, L., \u021aarc\u0103, E., Mois\u0103, \u0218.M., Trandafir, L.M., Stoleriu, S., B\u0103descu, M.C., Luca, A.C., and Popa, S. (2022). The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012199"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:51:24Z","timestamp":1778691084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103739"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103739","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}